KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Depreciation & Amortization (CF): 2012-2024

Historic Depreciation & Amortization (CF) for Travere Therapeutics (TVTX) over the last 13 years, with Dec 2024 value amounting to $43.6 million.

  • Travere Therapeutics' Depreciation & Amortization (CF) rose 40.48% to $15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.7 million, marking a year-over-year increase of 33.56%. This contributed to the annual value of $43.6 million for FY2024, which is 13.04% up from last year.
  • Per Travere Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $43.6 million for FY2024, which was up 13.04% from $38.5 million recorded in FY2023.
  • In the past 5 years, Travere Therapeutics' Depreciation & Amortization (CF) registered a high of $43.6 million during FY2024, and its lowest value of $12.7 million during FY2021.
  • In the last 3 years, Travere Therapeutics' Depreciation & Amortization (CF) had a median value of $38.5 million in 2023 and averaged $34.3 million.
  • As far as peak fluctuations go, Travere Therapeutics' Depreciation & Amortization (CF) crashed by 48.14% in 2021, and later surged by 85.96% in 2023.
  • Over the past 5 years, Travere Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $24.6 million in 2020, then slumped by 48.14% to $12.7 million in 2021, then spiked by 62.55% to $20.7 million in 2022, then skyrocketed by 85.96% to $38.5 million in 2023, then grew by 13.04% to $43.6 million in 2024.